Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
J Ryan Bariola, PharmD Erin K Mccreary, MD Richard J Wadas, PhD Kevin E Kip, MD Oscar C Marroquin, MSN Tami Minnier, BS Stephen Koscumb, BS Kevin Collins, MD Mark Schmidhofer, Judith A Shovel, MT Mary Kay Wisniewski, Colleen Sullivan, MD Donald M Yealy, MD MPH David A Nace, MD MPH David T Huang, MD Ghady Haidar, Tina Khadem, MS Kelsey Linstrum, MD MSc Christopher W Seymour, MS Stephanie K Montgomery, MD MPH FRCP Derek C Angus, MD SM Graham M Snyder
doi:10.1101/2021.03.25.21254322
Background: Monoclonal antibody (mAb) treatment may prevent complications of COVID-19. We sought to quantify the impact of bamlanivimab monotherapy on hospitalizations and mortality, as well as Emergency Department (ED) visits without hospitalization, among outpatients at high risk of COVID-19 complications.
Methods: We compared patients receiving mAb to patients who met criteria but did not receive mAb from December 2020 through March 2021. The study population selection used propensity scores to match 1:1 by likelihood to receive mAb. The primary outcome was hospitalization or all-cause mortality within 28 days; the secondary outcome was hospitalization or ED visit without hospitalization within 28 days. Odds ratios (OR) calculation used logistic regression modeling including propensity score and mAb receipt predictors.
Results: The study population included 234 patients receiving mAb and 234 matched comparator patients not receiving mAb. Patients receiving mAb were less likely to experience hospitalization or mortality (OR 0.31, 95% confidence interval [95%CI] 0.17-0.56, p=0.00001) and hospitalization or ED visit without hospitalization (OR 0.50, 95%CI 0.43-0.83, p=0.007). The impact of mAb was more pronounced in prevention of hospitalization (among all age groups, OR 0.35, 95%CI 0.19-0.66, p=0.001) than mortality or ED visit without hospitalization, and most strongly associated with patients age 65 years and older (primary outcome OR 0.28, 95%CI 0.14-0.56, p=0.0003).
Conclusions : Bamlanivimab monotherapy was associated with reduction in the composite outcome of hospitalizations and mortality in patients with mild-moderate COVID-19. The benefit may be strongest in preventing hospitalization in patients ages 65 years or older. . CoV016; Eli Lilly), casirivimab 1,200mg (REGN10933; Regeneron), imdevimab 1,200mg (REGN10987). Several clinical trials currently evaluate mAbs for prevention or treatment of COVID-19; however, real-world data are limited, and the role of mAbs for patients with COVID-19 remains controversial. 3, 5 Use of mAb therapy is low in the United States despite widespread drug availability due to lack of robust efficacy data, operational challenges with outpatient infusions, and patient access issues. 6 Our health system established a mAb program in November 2020 to decrease COVID-19-related complications for patients with mild-moderate illness and expand access to care for underserved patients with COVID-19. Initially, only bamlanivimab monotherapy was available; our evaluation and distribution process has been described elsewhere. 7 This study quantifies the impact of bamlanivimab monotherapy on hospitalizations, mortality, and Emergency Department (ED) visits among outpatients at high risk of progressing to severe COVID-19. We also explored whether patient age, body mass index, and timing of infusions relative to initial diagnosis had any association with response to therapy.
METHODS
Study Setting .
Conflict of Interest Disclosure: None of the authors received any payments or influence from a third-party source for the work presented, and none report any potential conflicts of interest.
SUPPLEMENTAL MATERIALS
References
Ault, Rollout of COVID Monoclonal Antibodies Lacked Unified Plan: Expert Panel
Austin, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies, Multivariate Behav Res. May,
doi:10.1080/00273171.2011.568786Bajaj, Gadi, Spihlman, Wu, Choi et al., Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?, Front Physiol,
doi:10.3389/fphys.2020.571416Bariola, Mccreary, Khadem, Snyder, Wadas et al., Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic, Open Forum Infect Dis
Benchimol, Smeeth, Guttmann, The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement, PLoS Med,
doi:10.1371/journal.pmed.1001885Chen, Nirula, Heller, SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2029849Cohen1, Nirula2, Mulligan3, Novak4, Marovich5 et al., ). Bamlanivimab prevents COVID-19 morbidity and mortality in nursinghome setting
Gottlieb, Nirula, Chen, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, Jama,
doi:10.1001/jama.2021.0202Jones, Brown-Augsburger, Corbett, LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection, bioRxiv,
doi:10.1101/2020.09.30.318972Lim, Subramaniam, Reddy, Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis, Am J Respir Crit Care Med. Jan,
doi:10.1164/rccm.202006-2405OCReitz, Marroquin, Zenati, Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes, JAMA Surg. Jun,
doi:10.1001/jamasurg.2020.0416Richardson, Hirsch, Narasimhan, Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA,
doi:10.1001/jama.2020.6775Rosenbaum, Db, The central role of the propensity score in observational studies for causal effects, Biometrika,
doi:10.1093/biomet/70.1.41Tartof, Qian, Hong, Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization, Ann Intern Med. Nov,
doi:10.7326/m20-3742Webb, Buckel, Vento, Real-World Effectiveness and Tolerability of Monoclonal Antibodies for Ambulatory Patients with Early COVID-19,
doi:10.1101/2021.03.15.21253646Weinreich, Sivapalasingam, Norton, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2035002{ 'institution': [{'name': 'medRxiv'}],
'indexed': {'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T23:49:26Z', 'timestamp': 1709336966122},
'posted': {'date-parts': [[2021, 3, 30]]},
'group-title': 'Infectious Diseases (except HIV/AIDS)',
'reference-count': 19,
'publisher': 'Cold Spring Harbor Laboratory',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'accepted': {'date-parts': [[2021, 3, 30]]},
'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Monoclonal '
'antibody (mAb) treatment may prevent complications of COVID-19. We sought to quantify the '
'impact of bamlanivimab monotherapy on hospitalizations and mortality, as well as Emergency '
'Department (ED) visits without hospitalization, among outpatients at high risk of COVID-19 '
'complications.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We '
'compared patients receiving mAb to patients who met criteria but did not receive mAb from '
'December 2020 through March 2021. The study population selection used propensity scores to '
'match 1:1 by likelihood to receive mAb. The primary outcome was hospitalization or all-cause '
'mortality within 28 days; the secondary outcome was hospitalization or ED visit without '
'hospitalization within 28 days. Odds ratios (OR) calculation used logistic regression '
'modeling including propensity score and mAb receipt '
'predictors.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The study '
'population included 234 patients receiving mAb and 234 matched comparator patients not '
'receiving mAb. Patients receiving mAb were less likely to experience hospitalization or '
'mortality (OR 0.31, 95% confidence interval [95%CI] 0.17-0.56, p=0.00001) and hospitalization '
'or ED visit without hospitalization (OR 0.50, 95%CI 0.43-0.83, p=0.007). The impact of mAb '
'was more pronounced in prevention of hospitalization (among all age groups, OR 0.35, 95%CI '
'0.19-0.66, p=0.001) than mortality or ED visit without hospitalization, and most strongly '
'associated with patients age 65 years and older (primary outcome OR 0.28, 95%CI 0.14-0.56, '
'p=0.0003).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Bamlanivimab '
'monotherapy was associated with reduction in the composite outcome of hospitalizations and '
'mortality in patients with mild-moderate COVID-19. The benefit may be strongest in preventing '
'hospitalization in patients ages 65 years or older.</jats:p></jats:sec>',
'DOI': '10.1101/2021.03.25.21254322',
'type': 'posted-content',
'created': {'date-parts': [[2021, 3, 30]], 'date-time': '2021-03-30T15:40:11Z', 'timestamp': 1617118811000},
'source': 'Crossref',
'is-referenced-by-count': 3,
'title': 'Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized '
'adults with SARS-CoV-2 infection',
'prefix': '10.1101',
'author': [ {'given': 'J. Ryan', 'family': 'Bariola', 'sequence': 'first', 'affiliation': []},
{'given': 'Erin K.', 'family': 'McCreary', 'sequence': 'additional', 'affiliation': []},
{'given': 'Richard J.', 'family': 'Wadas', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kevin E.', 'family': 'Kip', 'sequence': 'additional', 'affiliation': []},
{'given': 'Oscar C.', 'family': 'Marroquin', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tami', 'family': 'Minnier', 'sequence': 'additional', 'affiliation': []},
{'given': 'Stephen', 'family': 'Koscumb', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kevin', 'family': 'Collins', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mark', 'family': 'Schmidhofer', 'sequence': 'additional', 'affiliation': []},
{'given': 'Judith A.', 'family': 'Shovel', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mary Kay', 'family': 'Wisniewski', 'sequence': 'additional', 'affiliation': []},
{'given': 'Colleen', 'family': 'Sullivan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Donald M.', 'family': 'Yealy', 'sequence': 'additional', 'affiliation': []},
{'given': 'David A', 'family': 'Nace', 'sequence': 'additional', 'affiliation': []},
{'given': 'David T.', 'family': 'Huang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ghady', 'family': 'Haidar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tina', 'family': 'Khadem', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kelsey', 'family': 'Linstrum', 'sequence': 'additional', 'affiliation': []},
{'given': 'Christopher W.', 'family': 'Seymour', 'sequence': 'additional', 'affiliation': []},
{'given': 'Stephanie K.', 'family': 'Montgomery', 'sequence': 'additional', 'affiliation': []},
{'given': 'Derek C.', 'family': 'Angus', 'sequence': 'additional', 'affiliation': []},
{'given': 'Graham M.', 'family': 'Snyder', 'sequence': 'additional', 'affiliation': []}],
'member': '246',
'reference': [ { 'key': '2021040110400618000_2021.03.25.21254322v1.1',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.09.30.318972'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.2',
'unstructured': 'Myron S. Cohen 1, Ajay Nirula 2, Mark Mulligan 3, Richard Novak 4, Mary '
'Marovich 5, Alexander Stemer 6, Andrew C. Adams 2, Andrew E. Schade 2, '
'Jack Knorr 2, Jay L. Tuttle 2, Janelle Sabo 2, Paul Klekotka 2, Lei Shen '
'2, Daniel M. Skovronsky 2, for BLAZE-2 study team (Lilly/NIAID/CoVPN). '
'Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home '
'setting. Oral abstract #121. Presented at Virtual CROI 2021.'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.3',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2021.0202'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.4',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2035002'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.5',
'doi-asserted-by': 'crossref',
'unstructured': 'Webb BJ , Buckel W , Vento T , et al. Real-World Effectiveness and '
'Tolerability of Monoclonal Antibodies for Ambulatory Patients with Early '
'COVID-19. 3/17/2021 2021;doi: '
'https://doi.org/10.1101/2021.03.15.21253646',
'DOI': '10.1101/2021.03.15.21253646'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.6',
'unstructured': 'Ault A. Rollout of COVID Monoclonal Antibodies Lacked Unified Plan: '
'Expert Panel. Accessed 23 Mar 2021. Available at: '
'https://www.medscape.com/viewarticle/945223.'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.7',
'doi-asserted-by': 'crossref',
'unstructured': 'Bariola JR , McCreary EK , Khadem T , Snyder GM , Wadas RJ , Nace DA , '
'White DB , Yealy DM , Schmidhofer M. Establishing a Distribution Network '
'for COVID-19 Monoclonal Antibody Therapy Across a Large Health System '
'During a Global Pandemic. Open Forum Infect Dis. 2021. In press.',
'DOI': '10.1093/ofid/ofab151'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.8',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamasurg.2020.0416'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.9',
'unstructured': 'FDA News Release. Coronavirus (COVID-19) update: FDA authorizes '
'monoclonal antibody for treatment of COVID-19. Published November 9, '
'2020. Accessed November 13, 2020. https://bit.ly/2HesBBs.'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.10',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/00273171.2011.568786'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.11',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/biomet/70.1.41'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.12',
'doi-asserted-by': 'publisher',
'DOI': '10.1164/rccm.202006-2405OC'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.13',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2020.6775'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.14',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fphys.2020.571416'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.15',
'doi-asserted-by': 'publisher',
'DOI': '10.7326/m20-3742'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.16',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pmed.1001885'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.17',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2029849'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.18',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2021.02.16.431305'},
{ 'key': '2021040110400618000_2021.03.25.21254322v1.19',
'unstructured': 'US Department of Health and Human Services. Update on COVID-19 variants '
'and impact on bamlanivimab distribution. Available from: '
'https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab/Pages/default.aspx. '
'Accessed March 24th, 2021.'}],
'container-title': [],
'original-title': [],
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.03.25.21254322',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 12, 15]],
'date-time': '2021-12-15T15:07:14Z',
'timestamp': 1639580834000},
'score': 1,
'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.03.25.21254322'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 3, 30]]},
'references-count': 19,
'URL': 'http://dx.doi.org/10.1101/2021.03.25.21254322',
'relation': { 'is-preprint-of': [ { 'id-type': 'doi',
'id': '10.1093/ofid/ofab254',
'asserted-by': 'subject'}]},
'published': {'date-parts': [[2021, 3, 30]]},
'subtype': 'preprint'}
